HA-TAZ-S89A Citations (11)
Originally described in: TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway.Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL Mol Cell Biol. 2008 Apr;28(7):2426-36. Epub 2008 Jan 28. PubMed Journal
Articles Citing HA-TAZ-S89A
| Articles |
|---|
| Differential topical susceptibility to TGFbeta in intact and injured regions of the epithelium: key role in myofibroblast transition. Speight P, Nakano H, Kelley TJ, Hinz B, Kapus A. Mol Biol Cell. 2013 Nov;24(21):3326-36. doi: 10.1091/mbc.E13-04-0220. Epub 2013 Sep 4. PubMed |
| Context-dependent switch in chemo/mechanotransduction via multilevel crosstalk among cytoskeleton-regulated MRTF and TAZ and TGFbeta-regulated Smad3. Speight P, Kofler M, Szaszi K, Kapus A. Nat Commun. 2016 May 18;7:11642. doi: 10.1038/ncomms11642. PubMed |
| Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. Feng J, Yang H, Zhang Y, Wei H, Zhu Z, Zhu B, Yang M, Cao W, Wang L, Wu Z. Oncogene. 2017 Oct 19;36(42):5829-5839. doi: 10.1038/onc.2017.188. Epub 2017 Jun 12. PubMed |
| Sulforaphane reduces YAP/Np63alpha signaling to reduce cancer stem cell survival and tumor formation. Fisher ML, Ciavattone N, Grun D, Adhikary G, Eckert RL. Oncotarget. 2017 Aug 27;8(43):73407-73418. doi: 10.18632/oncotarget.20562. eCollection 2017 Sep 26. PubMed |
| Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells. Fisher ML, Grun D, Adhikary G, Xu W, Eckert RL. Oncotarget. 2017 Nov 22;8(66):110257-110272. doi: 10.18632/oncotarget.22628. eCollection 2017 Dec 15. PubMed |
| Type I collagen deposition via osteoinduction ameliorates YAP/TAZ activity in 3D floating culture clumps of mesenchymal stem cell/extracellular matrix complexes. Komatsu N, Kajiya M, Motoike S, Takewaki M, Horikoshi S, Iwata T, Ouhara K, Takeda K, Matsuda S, Fujita T, Kurihara H. Stem Cell Res Ther. 2018 Dec 7;9(1):342. doi: 10.1186/s13287-018-1085-9. PubMed |
| SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma. Isfort I, Cyra M, Elges S, Kailayangiri S, Altvater B, Rossig C, Steinestel K, Grunewald I, Huss S, Esseling E, Mikesch JH, Hafner S, Simmet T, Wozniak A, Schoffski P, Larsson O, Wardelmann E, Trautmann M, Hartmann W. Clin Cancer Res. 2019 Jun 15;25(12):3718-3731. doi: 10.1158/1078-0432.CCR-17-3553. Epub 2019 Feb 27. PubMed |
| Yap/Taz regulate alveolar regeneration and resolution of lung inflammation. LaCanna R, Liccardo D, Zhang P, Tragesser L, Wang Y, Cao T, Chapman HA, Morrisey EE, Shen H, Koch WJ, Kosmider B, Wolfson MR, Tian Y. J Clin Invest. 2019 Apr 15;130:2107-2122. doi: 10.1172/JCI125014. eCollection 2019 Apr 15. PubMed |
| Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells. Van Sciver N, Ohashi M, Pauly NP, Bristol JA, Nelson SE, Johannsen EC, Kenney SC. PLoS Pathog. 2021 Aug 2;17(8):e1009783. doi: 10.1371/journal.ppat.1009783. eCollection 2021 Aug. PubMed |
| RhoA-ROCK competes with YAP to regulate amoeboid breast cancer cell migration in response to lymphatic-like flow. Mohammadalipour A, Diaz MF, Livingston M, Ewere A, Zhou A, Horton PD, Olamigoke LT, Lamar JM, Hagan JP, Lee HJ, Wenzel PL. FASEB Bioadv. 2022 Feb 14;4(5):342-361. doi: 10.1096/fba.2021-00055. eCollection 2022 May. PubMed |
| An indispensable role of TAZ in anoikis resistance promoted by OTUB1 deubiquitinating enzyme in basal-like triple-negative breast cancer cells. Nakagawa H, Higurashi M, Ishikawa F, Mori K, Shibanuma M. Biochem Biophys Res Commun. 2023 Mar 15;649:1-9. doi: 10.1016/j.bbrc.2023.01.080. Epub 2023 Jan 26. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.